pentobarbital will decrease the extent or influence of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Observe.

pentobarbital will minimize the extent or result of nitrendipine by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Minimal/Importance Mysterious.

pentobarbital will lessen the level or impact of pioglitazone by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Slight/Significance Unknown.

pentobarbital will reduce the extent or influence of paclitaxel protein certain by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Small/Importance Unfamiliar.

pentobarbital will minimize the extent or result of quinidine by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

Aged or debilitated people may perhaps respond to barbiturates with marked melancholy, enjoyment, and confusion; in a few individuals, barbiturates frequently create excitement instead of despair

pentobarbital will minimize the level or influence of tofacitinib by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Loss of, or decreased response to tofacitinib may possibly manifest when coadministered with potent CYP3A4 inducers

Drugs that require prior authorization. This restriction involves that precise clinical criteria be fulfilled prior to the approval with the prescription.

Contraindicated (1)pentobarbital will lower the level or effect of dienogest/estradiol valerate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Women must not pick out estradiol valerate/dienogest as their contraceptive when utilizing sturdy CYP3A4 inducers as a result of potential decrease in contraceptive efficacy.

pentobarbital decreases levels of ponatinib by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Stay clear of or Use Alternate Drug. Stay clear of unless the coadministration outweighs the achievable possibility of ponatinib underexposure; observe for indications of lessened efficacy.

C: Use with warning if Gains outweigh dangers. Animal reports clearly show risk and human scientific studies not readily available or neither animal nor human experiments done.

pentobarbital will decrease the level or effect of fostemsavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.

pentobarbital will lower the level or impact of midostaurin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Strong CYP3A4 inducers may decrease midostaurin concentrations causing diminished efficacy.

pentobarbital will boost website the amount or result of ivosidenib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Stay clear of or Use Alternate Drug. Coadministration of ivosidenib with solid CYP3A4 inducers reduced ivosidenib plasma concentrations.